Syntex/Chiron
Executive Summary
Research collaboration announced Sept, 8 will focus on the discovery and design of synthetic compounds that inhibit the interaction of cellular adhesion molecules (CAMs) such as selectins and integrins. Syntex will have exclusive worldwide rights to develop and market collaboratively discovered CAM inhibitors for inflammation, asthma, allergy and transplantation, and Chiron will have right to jointly discovered CAM inhibitors for infectious disease applications, oncology and ophthalmology. Each company will have the option to co-fund the other company's development program in return for profit sharing or royalties on the other company's sales.